An­ti­body biotech Di­ag­o­nal Ther­a­peu­tics lands $128M to pur­sue rare dis­eases

Di­ag­o­nal Ther­a­peu­tics has launched with $128 mil­lion to go af­ter an or­phan dis­ease that leads to chron­ic ane­mia, and an­oth­er an­ti­body for the same rare dis­ease that is al­so tar­get­ed by Mer­ck’s new­ly ap­proved drug, Win­re­vair. Just last week, the biotech was con­grat­u­lat­ing its chief sci­en­tif­ic of­fi­cer on his con­tri­bu­tions to the same Mer­ck drug.

The Cam­bridge, MA-based biotech came out of stealth on Wednes­day morn­ing with the seed and Se­ries A funds from blue-chip back­ers like BVF Part­ners and At­las Ven­ture. Ad­di­tion­al in­vestors in­clude Light­speed Ven­ture Part­ners, RA Cap­i­tal Man­age­ment, Fra­zier Life Sci­ences, Viking Glob­al In­vestors, Velos­i­ty Cap­i­tal and Check­point Cap­i­tal.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER